Company attributes
Other attributes
ISR Immune System Regulation is a Swedish company which performs research and development of anti-viral drugs. The company is publicly traded on the Swedish stock exchange under the symbol ISR.
ISR-48 is a novel treatment for viral infected patients, with a focus on HIV. ISR has conducted a Phase I and Phase IIa clinical trial of ISR-48 as a treatment for HIV "with excellent effects already after one month," the company says.The company has patented ISR-48.
Additionally, the company has other drugs under development. ISR-49 is an anti-HIV drug with a new chemistry that is the company expects to have a clinical advantage over ISR-48. ISR Immune System Regulation has signed a collaboration agreement with Isomerase Therapeutics based in Cambridge, United Kingdom to undertake the chemistry.
In addition, ISR is currently developing a second line of chemical entities were ISR-50 is the lead candidate. ISR-50 has immunostimulatory properties that we are currently exploring in vitro and in animal models of chronic infections such as tuberculosis.
ISR Immune System Regulation says it has applied for 11 patents overall.
The company's subsidiary, ISR HBV AB, which is generally focused on medical solutions for Hepatitis B, is developing its medical solution Immunolid ISR50 to be used to treat COVID-19. The drug candidate stimulates immune cells and activates them to kill virus-infected cells.
